Publications by authors named "A F el Hader"
The telomerase RNA component (Terc) constitutes a non-coding RNA critical for telomerase function, commonly associated with aging and pivotal in immunomodulation during inflammation. Our study unveils heightened susceptibility to pneumonia caused by ) in knockout () mice compared to both young and old infected counterparts. The exacerbated infection in mice correlates with heightened inflammation, manifested by elevated interleukin-1β (IL-1β) levels and activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome within the lung.
View Article and Find Full Text PDFAgeing is a major risk factor that contributes to increased mortality and morbidity rates during influenza A virus (IAV) infections. Macrophages are crucial players in the defense against viral infections and display impaired function during ageing. However, the impact of ageing on macrophage function in response to an IAV infection remains unclear and offers potential insight for underlying mechanisms.
View Article and Find Full Text PDFEffect of repulsive interaction and initial velocity on collective motion process.
Eur Phys J E Soft Matter
October 2024
Self-propelled collective motion is a highly complex phenomenon, necessitating advanced practical and theoretical tools for comprehension. The significance of studying collective motion becomes apparent in its diverse applications. For instance, addressing evacuation challenges in scenarios with multiple agents can be achieved through an examination of collective motion.
View Article and Find Full Text PDFBackground: Primary cardiac soft tissue sarcomas (CSTS) affect young adults, with dismal outcomes.
Objectives: The aim of this study was to investigate the clinical outcomes of patients with CSTS receiving immune checkpoint inhibitors (ICIs).
Methods: A retrospective, multi-institutional cohort study was conducted among patients with CSTS between 2015 and 2022.
Article Synopsis
- - Patients with paraneoplastic syndromes (PNS) are often excluded from clinical trials for immune checkpoint inhibitors (ICIs) due to potential safety risks, leading to a lack of real-world data on their efficacy and safety for these patients.
- - A study analyzed data from 109 PNS patients with solid tumors treated with ICIs between 2015 and 2022, finding that 29% of those with pre-existing PNS experienced exacerbations shortly after starting ICI therapy, and a significant portion required immunosuppressive treatment.
- - No significant differences in overall survival (OS) or time-to-next treatment (TTNT) were observed between patients with metastatic non-small cell lung cancer (mNSCLC) with P